This clinical trial is focused on studying the effects of certain treatments on a condition known as osteogenesis imperfecta, which is a genetic disorder characterized by fragile bones that break easily. The study will explore the use of a medication called teriparatide, followed by zoledronic acid, to see if this combination can reduce the number of bone fractures in participants. The effects of these medications will be compared to standard care, which may include no active treatment or the use of drugs known as bisphosphonates, depending on what the patient and their healthcare provider decide is best.
Participants in the study will first receive teriparatide for two years. This medication is given as an injection and is sometimes used to help strengthen bones. After this period, participants will receive zoledronic acid, which is administered as an infusion, to further support bone health. The study aims to determine if this treatment plan can effectively reduce the occurrence of fractures, which will be confirmed through imaging techniques like x-rays.
The study will also monitor other aspects such as the total number of fractures, bone pain, quality of life, and functional status over time. These will be assessed using various questionnaires and tools to ensure a comprehensive understanding of the treatment’s impact. The study is expected to last for several years, with regular follow-ups to track the participants’ progress and gather necessary data.
Denmark 
France 
Ireland 
The Netherlands 
